Journal Article

Association between Body Mass Index and Renal Outcomes Modified by Chronic Kidney Disease and Anemia: The Obesity Paradox for Renal Outcomes

Hung, Chi-Chih, Chang, Jer-Ming, Kuo, I-Ching, Lee, Jia-Jung, Shen, Feng-Ching, Niu, Sheng-Wen, Hwang, Shang-Jyh, Yu, Pei-Hua

2022

Overview

Obesity-related nephropathy is associated with renal function progression. However, some studies have associated a high body mass index (BMI) with improved renal outcomes—this is referred to as the obesity paradox for renal outcomes, especially in relation to advanced chronic kidney disease (CKD). Central obesity can explain the obesity paradox in all-cause mortality. However, whether obesity or central obesity is associated with renal outcomes (renal replacement therapy or a 50% decline in the estimated glomerular filtration rate) in patients with advanced CKD remains unclear. Our study included 3605 Asian patients with CKD stages 1–5 divided into six groups according to their BMI (between 15 and 35 kg/m2). Through linear regression, BMI was positively associated with hemoglobin and albumin at CKD stages 4 and 5. In the competing risk Cox regression model, a high BMI (27.5–35 kg/m2) was associated with renal outcomes at CKD stages 1–3, but not stages 4 and 5. A high BMI was associated with renal outcomes in patients with hemoglobin ≥11 g/dL, but not <11 g/dL. A high waist-to-hip ratio was not associated with renal outcomes. We conclude that the CKD stage and anemia may explain the obesity paradox in renal outcomes in patients with CKD.

• Publisher: MDPI AG,MDPI
• Subject: Anemia / Blood pressure / Body fat / Body mass index / Cancer / Cardiovascular disease / Clinical medicine / Comorbidity / Diabetes / Hemodialysis / Hypertension / Inflammation / Kidney diseases / Laboratories / Liver diseases / Malnutrition / Metabolic syndrome / Mortality / Normal distribution / Obesity / Population / Proteins / Renal replacement therapy / Statistical analysis / Triglycerides / Urine